261149
镥
ingot, 99.9% trace rare earth metals basis
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
Lu
化学文摘社编号:
分子量:
174.97
UNSPSC Code:
12352300
PubChem Substance ID:
EC Number:
231-103-0
MDL number:
InChI key
OHSVLFRHMCKCQY-UHFFFAOYSA-N
InChI
1S/Lu
SMILES string
[Lu]
assay
99.9% trace rare earth metals basis
form
ingot
reaction suitability
reagent type: catalyst
core: lutetium
resistivity
54 μΩ-cm, 20°C
bp
3402 °C (lit.)
mp
1663 °C (lit.)
density
9.84 g/mL at 25 °C (lit.)
Quality Level
Xuejuan Wang et al.
European journal of nuclear medicine and molecular imaging, 39(12), 1876-1885 (2012-08-29)
Targeting of tumours positive for somatostatin receptors (sst) with radiolabelled peptides is of interest for tumour localization, staging, therapy follow-up and targeted radionuclide therapy. The peptides used clinically are exclusively agonists, but recently we have shown that the radiolabelled somatostatin-based
S Shcherbinin et al.
Physics in medicine and biology, 57(18), 5733-5747 (2012-09-06)
We investigated the quantitative accuracy of SPECT/CT imaging studies as would be performed before and after targeted radionuclide therapy (TRT) using phantom experiments with (i) (99m)Tc, (ii) ¹⁷⁷Lu and (iii) ⁹⁰Y/¹⁷⁷Lu. While the experiment with (99m)Tc imitated a diagnostic scan
Jostein Dahle et al.
Anticancer research, 33(1), 85-95 (2012-12-26)
The monoclonal antibody against CD20, rituximab, alone, or as part of combination therapies, is standard therapy for non-Hodgkin's B-cell lymphoma. Despite significantly better clinical results obtained for beta-emitting radioimmunoconjugates (RICs), RICs targeting CD20 are not commonly used in medical practice
Ksenija R Kumrić et al.
Journal of separation science, 35(18), 2390-2398 (2012-09-22)
In this study, the mass transport resistance in liquid-phase microextraction (LPME) in a single hollow fiber was investigated. A mathematical model has been developed for the determination of the overall mass transfer coefficient based on the acceptor phase in an
Rebecca A Dumont et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(5), 762-769 (2013-03-16)
The gastrin-releasing peptide receptor (GRPr) is overexpressed in prostate cancer and is an attractive target for radionuclide therapy. In addition, inhibition of the protein kinase mammalian target of rapamycin (mTOR) has been shown to sensitize various cancer cells to the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持